Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05179824 · ClinicalTrials.gov registry record

Tempus Priority Study: A Pan-tumor Observational Study

A clinical trial of Breast Cancer and Prostate Cancer, sponsored by Tempus AI.

Active
Registry status
1,000
Enrollment target
2
Study locations

NCT05179824 is a study of Breast Cancer and Prostate Cancer that is active but no longer recruiting, run by Tempus AI. The registered enrollment target is 1,000 participants, below the 2,802-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (64% lower). The trial reports 2 study locations across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05179824, a study of Breast Cancer and Prostate Cancer, is active but no longer recruiting, sponsored by Tempus AI.

ACTIVE NOT RECRUITING
Registry status
1,000 participants
Enrollment target
2
Study locations

Study Summary

Observational study that will be collecting clinical and molecular health information from cancer patients who have received comprehensive genomic profiling and meet the specific eligibility criteria outlined for each cohort with the goal of conducting research to advance cancer care and create a dataset that furthers cancer research.

Interventions

  • OTHER Observation

Study Locations (2)

Texas

  • UT Southwestern - Dallas
  • Baylor College of Medicine - Houston

Trial Details

FieldValue
Enrollment Target 1,000 participants
Start Date 2020-10-19
Est. Completion 2030-10-19

Sponsor

Tempus AI

13 total trials

What the Registry Record Tells You About NCT05179824

The ClinicalTrials.gov registry entry for NCT05179824 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 1,000 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,802-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (64% lower). The listed sponsor is Tempus AI, which has 13 total studies on file at ClinicalTrials.gov.

The record links to 10 conditions, with Breast Cancer appearing as the primary indexed condition, and to 1 intervention - of which Observation is the first listed.

NCT05179824 reports 2 study locations spanning 1 distinct geographic area - top geographies include Texas.

Frequently Asked Questions

What is clinical trial NCT05179824 about?

NCT05179824 is a clinical study titled "Tempus Priority Study: A Pan-tumor Observational Study". Observational study that will be collecting clinical and molecular health information from cancer patients who have received comprehensive genomic profiling and meet the specific eligibility criteria outlined for each cohort with the goal of conducting research to advance cancer care and create a da...

What is the current status of trial NCT05179824?

This trial is currently active not recruiting. The enrollment target is 1,000 participants. The study started on 2020-10-19. Estimated completion is 2030-10-19.

What conditions does trial NCT05179824 study?

This clinical trial studies the following conditions: Breast Cancer, Prostate Cancer, Lung Cancer, Ovarian Cancer, Pancreatic Cancer.

What interventions are being tested in trial NCT05179824?

The interventions under investigation include: Observation (OTHER).

Who is sponsoring clinical trial NCT05179824?

This trial is sponsored by Tempus AI, which has 13 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05179824 being conducted?

This trial has 2 study locations across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Breast Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.